Admission to Apex segment of AQSE Growth Market

Admission to the Apex segment of the AQSE Growth

EDX Medical Group plc (AQSE: EDX) ("EDX Medical" or the "Company"), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, is pleased to announce that it's ordinary shares are now eligible to commence trading on the Apex segment of the Aquis Stock Exchange ("AQSE") with effect from Monday, 29th April, 2024.

The Apex segment is reserved for larger, more established businesses with a proven growth strategy and which meet high standards of corporate governance. These strict eligibility criteria include having at least 25% of shares in public hands, a minimum of 25 shareholders and a two-year consolidated trading history and compliance with the QCA Code or the UK corporate governance code.

Dr Mike Hudson, CEO, EDX Medical Group plc, said:

"We are delighted to become part of the Apex segment on the Aquis Stock Exchange. This move reflects the success of our growth strategy since admission to the market in November 2022 and the evolution of our business. We were particularly pleased with the support from investors during our successful fund raising earlier this year which enables us to accelerate our product development programme. Our move to the Apex segment will provide further visibility for investors, and we welcome the increased emphasis on transparency, liquidity, and corporate governance, which align strongly with our own values."

Alasdair Haynes, CEO, Aquis Exchange plc, said:

"We are delighted to see EDX Medical move up to the Apex segment of the Aquis Stock Exchange Growth Market. It's fantastic to see how the company has progressed so far, and I am proud that Aquis can offer a tailored experience for growth companies that allows for increased exposure to investors at appropriate stages."

The board of directors of EDX Medical plc accept responsibility for this announcement.